Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.
Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.
Senseonics Holdings, Inc. (NYSE American: SENS) announced key financial and operational updates, projecting fourth-quarter 2020 net revenue of approximately $3.5 million, up from earlier estimates of $2.5 million. Full-year 2021 revenue is expected between $12 and $15 million. The FDA has delayed the marketing review of the Eversense 180-day product by at least 60 days due to resource reallocation for COVID-19. Notably, Eversense received inclusion in the 2021 CMS Physician Fee Schedule, improving access for Medicare patients as the company transitions distribution to Ascensia.